SNAR-C1: A Drug Target / Disease Biomarker (G100170225)

Target Name: SNAR-C1

NCBI ID: G100170225

SNAR-C1

Other Name(s): Small NF90 (ILF3) associated RNA C1 | small NF90 (ILF3) associated RNA C1

SNAR-C1: A Drug Target / Disease Biomarker

SNAR-C1 is a protein that is expressed in the brain and is known for its role in the regulation of cell death and neurodegeneration. The protein is derived from the neurotransmitter GABA, which is a well-known inhibitory neurotransmitter that has been linked to a number of cognitive and neurological benefits. GABA is known for its ability to protect brain cells from damage and its role in modulating the activity of a number of different neurotransmitters, including pain, anxiety, and depression.

SNAR-C1 is a 21-kDa protein that is expressed in the brain and is primarily localized to the endoplasmic reticulum (ER). It is characterized by a number of unique features that make it an attractive potential drug target. First, SNAR-C1 is highly resistant to both heat and cold temperatures, which suggests that it could be used as a therapeutic agent to treat a variety of conditions that involve inflammation or thermal injury. Second, SNAR-C1 is able to cross the blood-brain barrier (BBB), which is a specialized barrier that helps to protect the brain from foreign substances. This allows for the potential use of SNAR-C1 as a drug that can treat a variety of conditions that involve the central nervous system (CNS).

In addition to its unique physical properties, SNAR-C1 is also characterized by a number of unique functions. For example, it is involved in the regulation of cell death, which is a critical process that helps to remove damaged or dysfunctional cells from the brain. SNAR-C1 is also involved in the regulation of neurotransmitter signaling, which is important for the proper functioning of the brain.

SNAR-C1 is also of interest as a potential biomarker for a variety of neurological conditions. For example, it has been shown to be decreased in individuals with Alzheimer's disease, a degenerative brain disorder that is characterized by the progressive loss of brain cells. Additionally, SNAR-C1 has been shown to be decreased in individuals with other neurological conditions, such as depression and anxiety. These findings suggest that SNAR-C1 may be a useful biomarker for a variety of neurological conditions.

Given its unique properties and functions, SNAR-C1 is an attractive potential drug target. Studies have shown that SNAR-C1 can be modulated by a variety of small molecules, including drugs that are currently being used to treat a variety of neurological conditions. For example, research has shown that SNAR-C1 can be modulated by inhibitors of glutamate, a neurotransmitter that is involved in many different functions in the brain. Additionally, SNAR-C1 can be modulated by inhibitors of reactive oxygen species (ROS), which are highly reactive molecules that can cause damage to the brain.

In conclusion, SNAR-C1 is a protein that is derived from the neurotransmitter GABA and is expressed in the brain. It is characterized by its resistance to heat and cold temperatures and its ability to cross the blood-brain barrier. In addition to its unique physical properties, SNAR-C1 is also involved in the regulation of cell death and neurotransmitter signaling. These properties make SNAR-C1 an attractive potential drug target and a useful biomarker for a variety of neurological conditions. Further research is needed to fully understand the role of SNAR-C1 in the regulation of brain function and the development of effective treatments.

Protein Name: Small NF90 (ILF3) Associated RNA C1

The "SNAR-C1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNAR-C1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets